The race to set up the building blocks of the metaverse is on and many companies are hard at work establishing the world’s first open-source, decentralized virtual universe. This race has in part been galvanized by the rise of NFTs (Non-Fungible Tokens), whose values have shot up in price in direct correlation with rising cryptocurrency…
Now that 2021 has come to a close and leadership teams once again look to position their organizations for opportunities and challenges on the horizon, there’s no shortage of questions about what to expect in 2022 and beyond. Will technology fix the global supply chain crisis? Will “citizen data analysts” become the most important people […]
This article was published as a part of the Data Science Blogathon. Introduction Boosting is a key topic in machine learning. Numerous analysts are perplexed by the meaning of this phrase. As a result, in this article, we are going to define and explain Machine Learning boosting. With the help of “boosting,” machine learning models are […]
This article was published as a part of the Data Science Blogathon. Hey Folks! Welcome to the NLP from zero to advanced series on analytics Vidhya where we are covering all the NLP topics from beginner to the advanced level. In the last article, we have seen various text processing techniques with examples. If you haven’t […]
The Australian financial market regulator, ASIC, has selected five regulatory technology (regtech) companies to the Business Research and Innovation Initiative (BRII) to find a solution to the chal...
Event Details Mon, Jan 24, 2022 at 6:30 PM Ludlow House, 139 Ludlow St, New York, NY, 10002 More info: https://www.eventbrite.com/e/psychedelic-panel-series-new-york-tickets-250350935387 On Monday, January 24 at 6:30 p.m., Dustin Robinson, Esq. CPA, is bringing his Psychedelic Series that takes place monthly at Soho Beach House Miami to Ludlow House in New York. Hosted by Robinson, the panel will feature […]
Psychedelic-focused drug company Eleusis is merging with Silver Spike Acquisition Corp. II, a special purposes acquisition company, and heading to the Nasdaq with a combined enterprise value of $446 million. London-based Eleusis is a pioneer in the development of psychedelic drug candidates. The company’s lead asset, ELE-Psilo, is expected to enter the clinic later this year as a potential […]